Despite considerable progress with the scale up of insecticide treated nets (ITNs), deployment of chemoprevention approaches, and the adoption of highly effective treatment since 2000, malaria remains a primary cause of childhood illness and death in sub-Saharan Africa.
The WHO-coordinated Malaria Vaccine Implementation Programme (MVIP) was designed to evaluate the public health use of the RTS,S vaccine, including whether caregivers would bring their children to clinics for the 4-dose regimen and the vaccine’s impact on reducing childhood illness and death from malaria.
13448
试点实施于2019年在加纳、肯尼亚和马拉维启动。
The pilot implementations were launched in Ghana, Kenya and Malawi in 2019.
Four years on, nearly 1.5 million children at risk have been reached with the malaria vaccine across the 3 countries in Africa and more than 4.5 million doses of RTS,S have been administered in pilot areas of moderate to high malaria transmission.
Pilot findings (after 24 months of vaccination) have shown that the malaria vaccine is safe and effective, and implementation has resulted in substantial reduction in deadly severe malaria – a decrease in hospitalizations and a drop in child deaths.